Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.

ClinicalTrials.gov 4 recruiting now early-phase tilt small index

NASH: early-phase trial registry

4 of 11 indexed NASH trials are currently recruiting, with more weight in Phase 1-2.

Corpus placement: #1,577 of 28,707 conditions by registered trial count.

11 US clinical trials · 4 currently recruiting · #1,577 of 28,707 conditions by registered trial count

NASH: 11 US clinical trials tracked, 4 recruiting.

NASH is the subject of 11 registered US clinical trials on ClinicalTrials.gov, 4 of them currently open to new participants. 1 are in Phase 3-4 (later-stage) and 4 in Phase 1-2 (earlier-stage). The most active sponsor is Neuraly, running 1 of these trials.

Enrollment posture brief

Registry condition nash

OPEN 4 | RECR 36% | LATE 1 | EARLY 4 | RANK #1577 | SPON 1

Nearest open-share peer: Blast Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive (36% recruiting · 11 trials)

Acute Pancreatitis81.8%Acute Stroke45.5%Acquired Brain Injury36.4%NASH (this)36%Acute Lung Injury9.1%
Open-enrollment share among volume-matched conditions near NASH

NASH lists 4 open slots (36% of 11 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →

Key findings

What ClinicalTrials.gov does not surface for NASH on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.

  1. NASH is recruiting below its size-band peers.

    4 of 11 indexed trials (36.4%) are open to enrollment, against a 46.5% average across 27,806 conditions with fewer than 20 trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.

  2. Sponsorship of NASH trials is spread across many organizations.

    Neuraly accounts for 1 of 11 trials (9.1%). 11 distinct sponsors appear on at least one study for this condition label.

  3. Typical NASH enrolment sits around 150 participants.

    Median target enrolment is 150 among the 11 trials that report a genuine target (sentinel values excluded). 3 of those (27.3%) plan for fewer than 100 participants.

  4. NASH splits between interventional and observational designs.

    7 interventional and 4 observational studies make up this index (63.6% interventional). Study type is sponsor-reported on ClinicalTrials.gov.

Phase 24Phase 31

Open and recent trials

11 total, page 1 of 1

RECRUITING 400 participants

Evaluation of Non-Invasive Tests for Metabolic Liver Disease

Foundation for the National Institutes of Health

NCT07122700

RECRUITING 150 participants

Androgens and NAFLD Longitudinal Cohort Study

University of California, San Francisco

NCT06124261

RECRUITING Phase 2 144 participants

Digoxin In NASH (CODIN)

Yale University

NCT06588699

RECRUITING NA 20 participants

Feasibility, Safety and Acceptability of a Mobile Health Delivered Exercise Training Program in Patients With Nonalcoholic Steatohepatitis

Milton S. Hershey Medical Center

NCT06195943

ACTIVE NOT RECRUITING Phase 3 700 participants

A Phase 3 Study to Evaluate the Effect of Resmetirom on Clinical Outcomes in Patients With Well-compensated NASH Cirrhosis (MAESTRO-NASH-OUTCOMES)

Madrigal Pharmaceuticals

NCT05500222

ACTIVE NOT RECRUITING 450 participants

LITMUS Imaging Study

University of Oxford

NCT05479721

ACTIVE NOT RECRUITING Phase 2 228 participants

Study to Evaluate the Efficacy and Safety of K-877-ER and CSG452 in Participants With NASH With Liver Fibrosis

Kowa Research Institute

NCT05327127

ACTIVE NOT RECRUITING Phase 2 67 participants

A Study to Evaluate DD01 in Overweight/Obese Subjects With MASLD/MASH

Neuraly

NCT06410924

ACTIVE NOT RECRUITING NA 24 participants

An Imaging-based Quantitative Biomarker Assay for NAFLD in Children

University of Wisconsin, Madison

NCT06354491

COMPLETED 233 participants

Study to Determine the Response to COVID-19 Vaccination and Prevalence of COVID-19 in Subjects With Chronic Liver Disease

National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)

NCT05669677

COMPLETED Phase 2 102 participants

ALG-055009 in Non-cirrhotic Adults With MASH (HERALD)

Aligos Therapeutics

NCT06342947

Phase Distribution

PhaseTrial count
Phase 2 4
Phase 3 1

Named interventions

Most-linked intervention names on NASH records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.

Placebo Drug
5 trials
ALG-055009 Drug
1 trials
CSG452 Drug
1 trials
K-877-ER Drug
1 trials
Ultrasound (US) Device
1 trials
DD01 Drug
1 trials
Resmetirom Drug
1 trials
Magnetic Resonance Imaging (MRI) Device
1 trials

US sites by state

Facility locations filed on NASH trials. A trial with sites in several states counts in each.

Florida 5 trials
California 4 trials
Texas 3 trials
Arizona 3 trials
Maryland 2 trials
Louisiana 2 trials
Georgia 2 trials
Arkansas 2 trials

Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.

What to do with this NASH page

11 registered trials, 4 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.

  • 4 NASH trials are currently recruiting, check eligibility criteria before contacting a site. Browse recruiting trials
  • Neuraly sponsors the most NASH trials on record, review their full trial history before evaluating a specific study. See Neuraly's trials
  • Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide

Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This NASH condition card totals 11 registered trials; most-linked intervention Placebo; top US site state Florida. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.